Printer Friendly

SYSTEMIX HIRES VICE PRESIDENT OF PRECLINICAL RESEARCH

 PALO ALTO, Calif., May 21 /PRNewswire/ -- SyStemix, Inc. (NASDAQ: STMX), today announced it has appointed Ronald Hoffman, M.D., as vice president, preclinical research. Dr. Hoffman was most recently a professor of medicine at Indiana University School of Medicine. As a leader in the field of hematopoietic stem cell research, Dr. Hoffman brings more than 22 years of scientific, clinical and medical experience to SyStemix. Dr. Hoffman will be responsible for conceiving, designing, planning and coordinating all preclinical research activities.
 "SyStemix is delighted to have attracted such a high caliber scientist. Ron's experience in building upon significant research programs in hematopoietic stem cell and megakaryocyte biology will significantly advance our scientific programs," said Linda Sonntag, Ph.D., president and chief executive officer.
 Prior to joining SyStemix, Dr. Hoffman, 47, was instrumental in the development of a large laboratory for multi-disciplinary clinical research, largely focused on stem cell and cytokine biology. During his tenure at Indiana University, Dr. Hoffman was also a Bruce K. Wiseman Professor of Medicine and the chief of hematology/oncology. Dr. Hoffman was previously an associate professor of internal medicine at Yale University.
 "I am thrilled and feel fortunate to join SyStemix, an innovative and exciting biotechnology company," said Dr. Hoffman. "The programs in stem cell and megakaryocyte biology and cytokine development which are being pursued at SyStemix overlap with the research efforts that I have pursued throughout my academic career. The ability to facilitate the transfer of these new innovative therapeutic modalities into clinical medicine allows me to pursue a lifelong goal and led to my acceptance of this new position."
 Dr. Hoffman received his M.D. from New York University, was a medical intern and first-year medical resident at McGill University, a second-year medical resident at Stanford University Hospital and a hematology fellow at Mt. Sinai Hospital in New York.
 SyStemix, Inc., based in Palo Alto, is primarily engaged in the development of cellular processes and products based on human hematopoietic stem cells, human megakaryocytes and megakaryocyte progenitors.
 -0- 5/21/93
 /CONTACT: Linda Sonntag, Ph.D., president and CEO of SyStemix, 415-813-6510; or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 212-979-9180, for SyStemix/
 (STMX)


CO: SyStemix, Inc. ST: California IN: MTC SU: PER

GK-TS -- NY008 -- 1087 05/21/93 08:54 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 21, 1993
Words:380
Previous Article:AMERICAN CLAIMS EVALUATION, INC.REPORTS FOURTH QUARTER AND YEAR END RESULTS
Next Article:NATIONSBANK TO HOST SERIES OF PUBLIC HEARINGS TO SEEK PUBLIC COMMENT ON ITS COMMUNITY INVESTMENT EFFORTS
Topics:


Related Articles
SYSTEMIX APPOINTS THREE SENIOR EXECUTIVES
HEAD STANFORD LAWYER JOHN SCHWARTZ JOINS SYSTEMIX
SYSTEMIX APPOINTS NATIONAL CANCER INSTITUTE SENIOR INVESTIGATOR AS DIRECTOR OF GENE THERAPY
ISIS PHARMACEUTICALS PROMOTES CHRISTOPHER MIRABELLI AND B. LYNNE PARSHALL
SYSTEMIX SIGNS COLLABORATIVE AGREEMENT WITH CENTRE LEON BERARD
SYSTEMIX REPORTS THIRD QUARTER AND NINE MONTH RESULTS
SYSTEMIX APPOINTS NEW VICE PRESIDENT FOR MEDICAL AFFAIRS
AVIRON ANNOUNCES NEW BOARD MEMBER AND TWO VICE PRESIDENTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters